Compare Coursera Inc (COUR) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Charles River Laboratories Intl. Inc — how do they compare? Coursera Inc trades at $5.24 (market cap $1.39B), while Charles River Laboratories Intl. Inc trades at $302.69 (market cap $14.23B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 10.2× Coursera Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Charles River Laboratories Intl. Inc for 33 Days on average.
| COUR | CRL | |
|---|---|---|
Market Cap | $1.39B | $14.23B |
Volume | 9,728,980 | 1,176,885 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $310.77 |
52-Week Low | $4.64 | $149.93 |
Typical Hold Time | 47 Days | 33 Days |
Enterprise Value | $648.49M | $17.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% with bearish technical signals despite positive analyst sentiment. The company shows improving revenue growth from $524M in 2022 to $758M in 2025, though net losses persist at -$51M. Recent news highlights strong institutional interest with Deutsche Bank acquiring 1.7M shares and unusual options activity indicating bullish speculation. The stock faces technical resistance at $5 with RSI suggesting potential overbought conditions near-term.
While analyst consensus remains bullish with a $7.40 price target (44% upside), execution risks from ongoing losses and competitive pressures in edtech warrant caution. The company's Project Helix AI platform and 44% subscriber growth provide catalysts, but profitability challenges and integration costs from recent acquisitions present headwinds for investor returns.
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
